Deep learning-based treatment planning for psma RPT

Active Project Grant Awarded Last action

Award ID
R01CA296305
Recipient
Awarding agency
Obligated
$2,930,072

Award facts

Assistance listing
93.395 Cancer Treatment Research
Completion date 36% complete
Place of performance
New Haven, CT 06519, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Prostate cancer (PCA) is one of the most prevalent cancers worldwide, with an estimated 1,111,700 new cases and 307,500 deaths in 2012, and is currently the second most common cancer in men, and fifth leading cancer mortality in men. Prostate-specific membrane antigen (psma) is a transmembrane marker which shows limited expression levels in healthy tissues such as colon and proximal tubules in kidneys, but is recognized as the most prostate-specific antigen yet identified. This has led to the rapid expansion of radiopharmaceutical therapy (RPT) in the treatment of metastatic castration resistant prostate cancers (mcrpc) using 177LU-psma compounds. Subjects receiving this treatment undergo pre-therapy diagnostic psma-pet scans, and can undergo spect/CT scans after each round of therapy due to the theranostic nature of 177LU. This marks a major advantage of RPT over chemotherapies, as the biodistribution of the therapeutic agent can be visualized with pet or spect - which enables the collection of pharmacokinetic data to perform dosimetry calculations to optimize treatment planning. Unfortunately, to date, all prostate RPT use a standard dose regimen of 6X200MCI irrespective of the size of the patient or the pharmacokinetics and biodistribution of the radiopharmaceutical which govern the actual dose imparted to both the tumor and at-risk healthy tissues. Here, we propose to address this limitation by utilizing the wealth of imaging data that can be generated in the course of 177LU-psma therapy. We propose to build models of 177LU-psma dosimetry using imaging information available from pre-treatment 68GA- or 18F-psma pet as well as 177LU-psma spect obtained during RPT to personalize the dose injected at each cycle. We propose to develop deep learning-assisted predictive models that allow for personalized estimation of dosimetry, and thus personalized treatment planning. Clinical markers such as PSA levels and GFR of clcr will be included as predictors.

Transactions

Action Obligated Date
Amendment $59,105
Amendment $531,942
Amendment $531,942
Amendment $602,361
Amendment $602,361
Original award $602,361

Subawards

Subrecipient Amount Awarded
Universitat Bern Scope of work Department of Nuclear Medicine, University of Bern is fully committed to the development of this project in the following tasks: Task Area 1:… $74,991

Quick answers

Who received award R01CA296305?

R01CA296305 was awarded to Yale Univ by National Cancer Institute (National Institutes of Health) on January 1, 2025.

How much is award R01CA296305 worth?

$2,930,072 has been obligated on R01CA296305.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login